SEC Tracker
Get the app

Madrigal Pharmaceuticals MDGL

M Daly James (Director) plans to sell 15,470 MDGL shares, about $5.4M

Form
144
Filed
Importance
Routine
  1. Approximate sale date: Feb 27, 2025
  2. Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
  3. Shares acquired by: Exercise of options under a registered plan

All of M Daly James's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 398 shares at $346.9 on Feb 27, 2025 · Form 4
  • Sold 14,302 shares at $347.39 on Feb 27, 2025 · Form 4
  • Sold 770 shares at $348.94 on Feb 27, 2025 · Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Madrigal Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Ionis Pharmaceuticals IONS public float $5.3B, Jun 30, 2025
  2. Repligen RGEN public float $6.0B, Jun 30, 2025
  3. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  4. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  5. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.